Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

25 Oct 2016 17:43

RNS Number : 4431N
GW Pharmaceuticals PLC
25 October 2016
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Julian Gangolli

2.

Reason for the notification

a.

Position/status

Director/President, US

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

 

c.

Price(s) and volume(s)

 

Price(s)

 0.1p

Volume(s)

10,608

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

 London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

301

 

ADS's issued upon conversion of 3,612 Ordinary shares

d.

Aggregated information

·Aggregated volume

·Price

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

 

American Depositary Shares

ISIN: 36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

 

Price(s)

 $120.75

Volume(s)

301

 

ADS's sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary Share and Restricted American Depositary Shares

Ordinary Shares: ISIN: GB0030544687

Restricted American Depositary shares: ISIN: US36197T1372

b.

Nature of the transaction

Conversion of Ordinary Shares into Restricted American Depositary shares (12 to 1 Conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

583

Restricted ADSs issued upon conversion of 6,996 Ordinary Shares

d.

Aggregated information

·Aggregated volume

·Price

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Christopher Tovey

2.

Reason for the notification

a.

Position/status

Director/Chief Operations Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

c.

Price(s) and volume(s)

 

Price(s)

 0.1p

Volume(s)

266,557

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

 London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

22,213

ADS's issued upon conversion of 266,556 Ordinary shares

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

American Depositary Shares

ISIN: US36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

 

Price(s)

 $120.36

Volume(s)

22,213

 

ADS's sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Geoffrey Guy

2.

Reason for the notification

a.

Position/status

Director/Chairman of the Board

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.43p

Volume(s)

206,100

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

21 October 2016

f.

Place of the transaction

 AIM, London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

 Ordinary Shares: ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.24

Volume(s)

68,900

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

AIM, London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

0.1 Pence Ordinary Shares

ISIN:GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.09

Volume(s)

125,000

 

Ordinary Shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

AIM, London

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Stephen Wright

2.

Reason for the notification

a.

Position/status

Director/Chief Medical Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares by the wife of Dr Stephen Wright

c.

Price(s) and volume(s)

 

Price(s)

 £8.10p

Volume(s)

1,556

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

 AIM, London

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFSRIILEFIR
Date   Source Headline
25th Nov 20097:02 amRNSPatient Recruitment Completed for Sativex Study
25th Nov 20097:00 amRNSFinal Results
23rd Nov 20097:00 amRNSPositive Sativex Results in Cancer Pain
4th Nov 200912:15 pmRNSNotice of Results
30th Oct 20094:43 pmRNSBlocklisting Interim Review
30th Oct 20093:41 pmRNSTotal Voting Rights
17th Sep 20094:40 pmRNSSecond Price Monitoring Extn
17th Sep 20094:35 pmRNSPrice Monitoring Extension
17th Sep 20097:00 amRNSUpdate on cannabinoid pipeline
14th Sep 20097:00 amRNSResults from two clinical studies of Savitex(R)
10th Sep 20097:00 amRNSRodman and Renshaw Conference
18th Aug 20094:23 pmRNSHolding(s) in Company
18th Aug 20094:18 pmRNSTotal Voting Rights
6th Aug 20097:00 amRNSRe Agreement
28th Jul 200911:10 amRNSDirector/PDMR Shareholding
16th Jul 20097:00 amRNSManufacturing Licence Received for Sativex
26th Jun 20098:41 amRNSDirector/PDMR Shareholding
24th Jun 20099:19 amRNSDirector/PDMR Shareholding
16th Jun 20097:00 amRNSGW Expands Cannabinoid Research
15th Jun 20095:46 pmRNSDirector/PDMR Shareholding
2nd Jun 20097:00 amRNSHolding(s) in Company
1st Jun 20094:12 pmRNSNotification of Interests of Directors
21st May 20094:00 pmRNSDirector/PDMR Shareholding
20th May 20097:01 amRNSGW Files Sativex? Regulatory Submission
20th May 20097:00 amRNSInterim Results
20th Apr 20093:20 pmRNSNotice of Results
1st Apr 20097:00 amRNS?8m Milestone Payment from Almirall
31st Mar 20097:00 amRNSBlocklisting Interim Review
31st Mar 20097:00 amRNSTotal Voting Rights
30th Mar 200910:11 amRNSDirector/PDMR Shareholding
27th Mar 20094:51 pmRNSDirector/PDMR Shareholding
13th Mar 20099:34 amRNSNotification of Interests of Directors
11th Mar 20091:12 pmRNSPositive Outcome of Sativex Phase III MS Study
2nd Mar 20095:38 pmRNSDirector/PDMR Shareholding
24th Feb 20097:00 amRNSClinical Trial Update
16th Jan 20095:27 pmRNSDirector/PDMR Shareholding
14th Jan 20092:05 pmRNSResult of AGM
2nd Dec 20085:50 pmRNSDirector/PDMR Shareholding
18th Nov 20087:00 amRNSFinal Results
24th Oct 20084:47 pmRNSSecond Price Monitoring Extn
24th Oct 20084:37 pmRNSPrice Monitoring Extension
22nd Oct 200811:00 amRNSNotice of Results
10th Oct 20084:42 pmRNSPrice Monitoring Extension
1st Oct 20087:00 amRNSTrial Completes Recruitment
8th Sep 20087:00 amRNSResearch Update
18th Jul 20084:38 pmRNSDirector/PDMR Shareholding
24th Jun 20083:36 pmRNSBlocklisting Interim Review
24th Jun 20083:32 pmRNSBlocklisting Interim Review
24th Jun 20083:27 pmRNSBlocklisting Interim Review
24th Jun 20083:22 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.